CDH17-targeted RLT / Corellia AI, Champions Oncology - LARVOL DELTA

A novel CDH17-targeted radioligand therapy overcomes resistance to microtubule and topoisomerase I inhibitor ADCs and achieves potent efficacy in GI-tract tumors (AACR 2026) - "We demonstrate that CDH17-targeted RLT shows broad and durable responses across the PDX panel, including full activity in models refractory to Deruxtecan-based ADCs, demonstrating the superiority of RLT in these indications in overcoming drug resistance and achieving durable responses. These data collectively support CDH17-targeted RLT as a promising therapeutic approach for CDH17-positive gastrointestinal malignancies."

ADC • Clinical • Colon Adenocarcinoma • Colon Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CDH17